Virginia Commonwealth University has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, myocardial infarction, arthritis, diabetes, gout, COVID-19, Alzheimer’s and Parkinson’s disease, among others.
Blueprint Medicines Corp. has identified KIT (c-KIT) (mutant) inhibitors reported to be useful for the treatment of gastrointestinal stromal tumors (GIST).
Kumquat Biosciences Inc. has synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are reported to be useful for the treatment of metabolic diseases, cancer, infections and more.
The America Invents Act of 2011 was designed to provide a durable overhaul of the U.S. patent system, but the inter partes review process has drawn fire from inventors as a patent-killing machine.
Researchers from the Weizmann Institute of Science in Rehovot, Israel, are seeking – through the university’s commercial arm, Yeda Research and Development Co. Ltd. – to gain patent protection for methods and systems for detecting and treating attention deficit hyperactivity disorder (ADHD) that are based on nasal respiration parameters.
Mindset Pharma Inc. has described indoline derivatives acting as 5-HT2A receptor agonists reported to be useful for the treatment of anhedonia, anorexia nervosa, epilepsy, fragile X syndrome, obsessive-compulsive disorder, post-traumatic stress, stroke and Alzheimer’s disease, among others.
Rome Therapeutics Inc. has divulged didehydro-3’-deoxy-4’-ethynylthymidines acting as LINE-1 retrotransposable element ORF1 protein (L1RE1) and/or HERV-K reverse transcriptase inhibitors reported to be useful for the treatment of cancer, autoimmune disease and neurological disorders.
Nimbus Clotho Inc. has identified CTP synthase 1 (CTPS1) inhibitors reported to be useful for the treatment of psoriasis, lichen planus, lupus nephritis, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, autoimmune lymphoproliferative syndrome, and graft-vs.-host disease.